Altimmune, Inc. (ALT)

SAN DIEGO , Dec. 11, 2025 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ALT5 Sigma Corporation (NASDAQ: ALTS) focused on whether ALT5 Sigma and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the ALT5 Sigma investigation or if you are an ALT5 Sigma investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-alt5-sigma-corporation-investigation-alts.html You can also contact attorneys J.C.

The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company,” “our” or “ALT5”) (NASDAQ: ALTS) (FRA:5AR1), a fintech company with established global payments, trading, and settlement infrastructure, today released a strategic overview on the USD1 stablecoin, its relevance to ALT5's core long-term payments technology product, and the anticipated benefits to the Company's $WLFI Treasury Strategy. Why USD1 Matters to ALT5 ALT5 is a leading holder of $WLFI, the governance token of the World Lib.

LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS) (FRA:5AR1), a fintech company advancing a strategic $WLFI digital asset treasury initiative, today issued a corporate update. Tony Issac, President and CEO of ALT5 commented, “ALT5's fintech success over the past several years stems from our nimble, startup-driven approach, one that enabled us to adapt quickly to market shifts and capitalize on emerging opportunities. We are focused on re-igniting that s.

LAS VEGAS--(BUSINESS WIRE)--ALT 5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1) today announced that it received a notification letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its delay in filing its Form 10-Q for the period ended September 27, 2025 (the “Form 10-Q”). On November 12, 2025, the Company filed a Notification of Late Filing on Form 12b-25 with the SE.

Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows:

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Altimmune, Inc. (NASDAQ: ALT - Get Free Report) saw unusually large options trading on Monday. Investors bought 11,978 call options on the stock. This represents an increase of 103% compared to the average daily volume of 5,887 call options. Institutional Trading of Altimmune Institutional investors have recently modified their holdings of the company. Victory Capital Management

Altimmune, Inc. ( ALT ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:00 AM EST Company Participants Vipin Garg - President, CEO & Director Christophe Arbet-Engels - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division All right. Good morning, everyone, to Jefferies' London Healthcare Conference 2025.

Altimmune remains a speculative buy as pemvidutide shows strong Phase IIb MASH results, confirmed by a recent Lancet publication. ALT's pemvidutide demonstrates significant MASH resolution, fibrosis improvement, and favorable safety, differentiating it from competitors and supporting a bullish long-term outlook. Risks include upcoming 48-week binary data, regulatory uncertainty, financial dilution, and heavy competition, but ALT's cash position reduces immediate offering risk.

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc.  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The Lancet of 24-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a paper titled “Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study”.

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement

Altimmune, Inc. ( ALT ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Vipin Garg - President, CEO & Director Linda Richardson - Chief Commercial Officer Gregory Weaver - Chief Financial Officer M. Roberts - Chief Scientific Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Patrick Trucchio - H.C.

48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer Cash, cash equivalents and short-term investments of $211 million as of September 30, 2025 Webcast to be held today, November 6, 2025, at 8:30 a.m. ET GAITHERSBURG, Md.

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 Fireside Chat at 10:00 a.m.